首页> 外文期刊>Bone marrow transplantation >Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature.
【24h】

Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature.

机译:异基因SCT治疗成人异色性白细胞营养不良和文献综述。

获取原文
获取原文并翻译 | 示例
           

摘要

Five patients with adult-onset metachromatic leukodystrophy (MLD) underwent allo-SCT. Conditioning was reduced in intensity and grafts were obtained from voluntary unrelated donors. All but one graft were depleted of T-lymphocytes. Patient age at transplantation varied from 18 to 29 (median, 27) years. Two patients rejected their graft and MLD progressed. The recipient of the unmanipulated graft converted to complete donor chimerism with normalization of arylsulphatase A (ARSA) levels. Despite ARSA normalization, he deteriorated. Another patient was a mixed chimera. Following escalated doses of donor lymphocyte infusions he converted to complete donor chimerism. His levels of ARSA correlated positively with the percentage of donor cells and MLD was not progressive. The fifth patient died after 35 days from complications associated with GVHD. We conclude that results of allo-SCT in symptomatic MLD patients are poor. However, allo-SCT may stop progression of MLD in selected patients.
机译:5名成人发作的异色性白细胞营养不良(MLD)患者接受了allo-SCT。调理强度降低,并从自愿的无亲属捐赠者那里获得了移植物。除一个移植物外,其余所有的T淋巴细胞均已耗尽。移植时的患者年龄从18岁到29岁(中位数为27岁)不等。两名患者拒绝了他们的移植物,MLD进展。未操作的移植物的受体转化为完全的供体嵌合,并且芳基硫酸酯酶A(ARSA)水平正常化。尽管ARSA正常化,他还是恶化了。另一例患者是混合嵌合体。在增加剂量的供体淋巴细胞输注后,他转化为完全的供体嵌合体。他的ARSA水平与供体细胞的百分比呈正相关,而MLD并不进展。第五名患者在与GVHD相关的并发症发生35天后死亡。我们得出结论,有症状的MLD患者的allo-SCT结果很差。但是,异源SCT可能会阻止某些患者发生MLD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号